ArcherDX: ArcherDX and UCL extend TRACERx program collaboration to evaluate cancer evolution
BOULDER and LONDON -- ArcherDX, Inc., UCL and the Francis Crick Institute today announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx
Read full article »
ArcherDX is a bioinformatics company that develops and commercializes NGS-based gene fusion detection assays for oncology applications.
Read more